Robert R Conley - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Robert R Conley

Showing results (41-50 of 113) with videos related to

Pageof 12

Sort By:

The Journal of Clinical Psychiatry|January 28, 2004

Academic highlights: guidelines for the use of long-acting injectable atypical antipsychoticsSamuel J Keith, John M Kane, Martin Turner, et al.

Journal of Child and Adolescent Psychopharmacology|May 15, 2004

Atypical antipsychotic use in a state hospital inpatient adolescent populationDeanna L Kelly, Raymond C Love, Marie MacKowick, et al.

The American Journal of Psychiatry|January 5, 2002

[(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victimsYogesh Dwivedi, Robert R Conley, Rosalinda C Roberts, et al.

Schizophrenia Research|November 18, 2006

The burden of depressive symptoms in the long-term treatment of patients with schizophreniaRobert R Conley, Haya Ascher-Svanum, Baojin Zhu, et al.

Journal of Clinical Psychopharmacology|November 19, 2003

The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover studyRobert R Conley, Deanna L Kelly, Charles M Richardson, et al.

Frontiers in Psychiatry|April 18, 2012

Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigraEmma Perez-Costas, Miguel Melendez-Ferro, Matthew W Rice, et al.

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|February 20, 2004

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley, Charles M Richardson, et al.

Schizophrenia Bulletin|December 16, 2006

Clozapine underutilization and discontinuation in African Americans due to leucopeniaDeanna L Kelly, Julie Kreyenbuhl, Lisa Dixon, et al.

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|June 24, 2008

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapineDeanna L Kelly, Robert R Conley, Raymond C Love, et al.

The Journal of Neuropsychiatry and Clinical Neurosciences|June 9, 2005

Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophreniaJoo-Cheol Shim, Young-Hoon Kim, Deanna L Kelly, et al.

Pageof 12

Search research articles

Showing results (41-50 of 113) with videos related to

Sort By:

Pageof 12

The Journal of Clinical Psychiatry|January 28, 2004

Academic highlights: guidelines for the use of long-acting injectable atypical antipsychoticsSamuel J Keith, John M Kane, Martin Turner, et al.

Journal of Child and Adolescent Psychopharmacology|May 15, 2004

Atypical antipsychotic use in a state hospital inpatient adolescent populationDeanna L Kelly, Raymond C Love, Marie MacKowick, et al.

The American Journal of Psychiatry|January 5, 2002

[(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victimsYogesh Dwivedi, Robert R Conley, Rosalinda C Roberts, et al.

Schizophrenia Research|November 18, 2006

The burden of depressive symptoms in the long-term treatment of patients with schizophreniaRobert R Conley, Haya Ascher-Svanum, Baojin Zhu, et al.

Journal of Clinical Psychopharmacology|November 19, 2003

The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover studyRobert R Conley, Deanna L Kelly, Charles M Richardson, et al.

Frontiers in Psychiatry|April 18, 2012

Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigraEmma Perez-Costas, Miguel Melendez-Ferro, Matthew W Rice, et al.

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|February 20, 2004

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley, Charles M Richardson, et al.

Schizophrenia Bulletin|December 16, 2006

Clozapine underutilization and discontinuation in African Americans due to leucopeniaDeanna L Kelly, Julie Kreyenbuhl, Lisa Dixon, et al.

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|June 24, 2008

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapineDeanna L Kelly, Robert R Conley, Raymond C Love, et al.

The Journal of Neuropsychiatry and Clinical Neurosciences|June 9, 2005

Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophreniaJoo-Cheol Shim, Young-Hoon Kim, Deanna L Kelly, et al.

Pageof 12